Lantheus Medical Imaging, Inc.
331 Treble Cove Road
North Billerica
Massachusetts
01862
United States
Tel: 800-299-3431
Website: http://www.lantheus.com/
Email: bi.webadmin@lantheus.com
About Lantheus Medical Imaging, Inc.
Lantheus Medical Imaging is a global leader in the development, manufacture and commercialization of innovative diagnostic imaging agents and products. LMI provides a broad portfolio of products, including the echocardiography contrast agent DEFINITY® Vial for (Perflutren Lipid Microsphere) Injectable Suspension and TechneLite® (Technetium Tc99m Generator), a technetium-based generator that provides the essential medical isotope used in nuclear medicine procedures. The Company is headquartered in North Billerica, Massachusetts with offices in Puerto Rico and Canada. For more information, visit www.lantheus.com.
Stock Exchange: NASDAQ
Stock Symbol: LNTH
153 articles about Lantheus Medical Imaging, Inc.
-
Lantheus Medical Imaging Commences Exchange Offer
4/11/2011
-
Lantheus Medical Imaging Announces Expiration of Consent Solicitation and Receipt of Requisite Consents
3/16/2011
-
Lantheus Medical Imaging Receives Special Protocol Assessment Approval from FDA for Phase 3 Trial of Flurpiridaz F-18 for the Diagnosis of Coronary Artery Disease
3/11/2011
-
Lantheus Medical Imaging Commences Consent Solicitation
3/4/2011
-
Lantheus Medical Imaging Announces Completion of Exchange Offer for Its 9.750% Senior Notes Due 2017
2/3/2011
-
Lantheus Medical Imaging Announces New National Contract with Novation for ABLAVAR(R) and DEFINITY(R)
1/21/2011
-
Lantheus Medical Imaging Announces Promotion of Robert Gaffey to Chief Financial Officer
1/18/2011
-
Lantheus Medical Imaging Extends Molybdenum-99 Contract with Nordion International
1/5/2011
-
Lantheus Medical Imaging Commences Exchange Offer
1/3/2011
-
Lantheus Medical Imaging Announces FDA Accepts for Review DEFINITY(R) Supplemental New Drug Application for Use in Stress Echocardiography
12/14/2010
-
Medical Scans, Without The Weapons-Grade Uranium Shipped to Lantheus Medical Imaging
12/7/2010
-
Lantheus Medical Imaging Selected to Participate in Premier Healthcare Alliance Comparative Effectiveness Research Program
12/7/2010
-
Lantheus Medical Imaging Announces First Commercial Production of Technelite(R) Generators from Low-Enriched Uranium-Produced Molybdenum-99
12/6/2010
-
Lantheus Medical Imaging Launches ABLAVAR(R) in Canada
10/14/2010
-
Lantheus Medical Imaging to Present Clinical Data on Investigational Cardiac PET Imaging Agents at American Society of Nuclear Cardiology
9/20/2010
-
Lantheus Medical Imaging Commends Safety Labeling Changes Announced by FDA for Gadolinium-Based Contrast Agents
9/10/2010
-
Lantheus Medical Imaging Launches DEFINITY(R) Ultrasound Contrast Imaging Agent in India
7/15/2010
-
Lantheus Medical Imaging Purchases Balance of Worldwide Rights for MRA Imaging Agent ABLAVAR(R) (Gadofosveset Trisodium)
7/12/2010
-
Lantheus Medical Imaging Announces Agreement with MDS Nordion to Secure Additional Supply of Molybdenum-99 (Mo-99), a Key Medical Isotope
7/8/2010
-
Lantheus Medical Imaging Presents Phase 4 Safety Data on DEFINITY(R) at American Society of Echocardiography Annual Meeting
6/14/2010